FENC Q4 2024 Earnings — Fennec Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

FENCFennec Pharmaceuticals Inc.

$220M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-20.8% YoY

Gross Profit

$7M91.6% margin

Operating Income

-$934,000-11.8% margin

Net Income

-$2M-25.0% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+13.6%

Cash Flow

Operating Cash Flow

-$1M

Free Cash Flow

-$1M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$45M

Total Liabilities

$51M

Stockholders' Equity

-$6M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$10M	-20.8%
Gross Profit	$7M	$9M	-22.0%
Operating Income	-$934,000	-$2M	+50.0%
Net Income	-$2M	-$3M	+28.0%